Peripheral endocannabinoid system dysregulation in first-episode psychosis

Neuropsychopharmacology

Volumn 38, Issue 13, 2013, Pages 2568-2577

  Bioque, Miquel ^a   García Bueno, Borja ^b,c   MacDowell, Karina S ^b,c   Meseguer, Ana ^a   Saiz, Pilar A ^d   Parellada, Mara ^e   Gonzalez Pinto, Ana ^f   Rodriguez Jimenez, Roberto ^c   Lobo, Antonio ^g   Leza, Juan C ^b,c   Bernardo, Miguel ^a,h  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d UNIVERSITY OF OVIEDO   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f HOSPITAL TXAGORRITXU   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^h UNIVERSITY OF BARCELONA   (Spain)

Author keywords

biomarker; cannabis; endocannabinoid system; first episode of psychosis; schizophrenia

Indexed keywords

ACYLGLYCEROL LIPASE; ARIPIPRAZOLE; BIOLOGICAL MARKER; CANNABIS; CHLORPROMAZINE; CLOZAPINE; ENDOCANNABINOID; FATTY ACID AMIDASE; LIPOPROTEIN LIPASE; N ACYL PHOSPHATIDYLETHANOLAMINE PHOSPHOLIPASE; OLANZAPINE; PALIPERIDONE; PHOSPHOLIPASE; QUETIAPINE; RISPERIDONE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOSIS; RISK FACTOR; WESTERN BLOTTING;

ADOLESCENT; ADULT; AMIDOHYDROLASES; CHILD; ENDOCANNABINOIDS; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MONOACYLGLYCEROL LIPASES; PHOSPHOLIPASE D; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RECEPTOR, CANNABINOID, CB2; YOUNG ADULT;

EID: 84887989932     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.165     Document Type: Article

References (65)

1. Aleman A, Kahn RS, Selten JP (2003). Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry 60: 565-571.
2. American Psychiatric Association (1994). DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th edn. American Psychiatric Association: Washington, DC.
3. Bangalore SS, Prasad KM, Montrose DM, Goradia DD, Diwadkar VA, Keshavan MS (2008). Cannabis use and brain structural alterations in first episode schizophrenia-a region of interest, voxel based morphometric study. Schizophr Res 99: 1-6.
4. Battista N, Meccariello R, Cobellis G, Fasano S, Di Tommaso M, Pirazzi V et al (2012). The role of endocannabinoids in gonadal function and fertility along the evolutionary axis. Mol Cell Endocrinol 355: 1-14.
5. Beltramo M, de Fonseca FR, Navarro M, Calignano A, Gorriti MA, Grammatikopoulos G et al (2000). Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J Neurosci 20: 3401-3407.
6. Bernardo M, Bioque M (2010). Schizophrenia: from neurobiology to nosology of mental disorders. Actas Esp Psiquiatr 38(Suppl 3): 15-17.
7. Bernardo M, Bioque M, Parellada M, Saiz Ruiz J, Cuesta MJ, Llerena A et al (2013). Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs). Rev Psiquiatr Salud Ment 6: 4-16.
8. Bilkei-Gorzo A (2012). The endocannabinoid system in normal and pathological brain ageing. Philos Trans R Soc Lond B Biol Sci 367: 3326-3341.
9. Boggs DL, Kelly DL, McMahon RP, Gold JM, Gorelick DA, Linthicum J et al (2012). Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophr Res 134: 207-210.
10. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H et al (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 57: 1117-1127.
11. Castro-Fornieles J, Parellada M, Soutullo CA, Baeza I, Gonzalez-Pinto A, Graell M et al (2008). Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach. J Child Adolesc Psychopharmacol 18: 327-336.
12. Centonze D, Battistini L, Maccarrone M (2008). The endocanna-binoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases. Curr Pharm Des 14: 2370-2442.
13. Chanda PK, Gao Y, Mark L, Btesh J, Strassle BW, Lu P et al (2010). Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol Pharmacol 78: 996-1003.
14. D'Souza DC, Sewell RA, Ranganathan M (2009). Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci 259: 413-431.
15. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V (2003). Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2: 5.
16. Desfosses J, Stip E, Bentaleb LA, Lipp O, Chiasson JP, Furtos A et al (2012). Plasma endocannabinoid alterations in individuals with substance use disorder are dependent on the "Mirror Effect" of schizophrenia. Front Psychiatry 3: 85.
17. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z et al (2001). Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410: 822-825.
18. Eggan SM, Hashimoto T, Lewis DA (2008). Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Arch Gen Psychiatry 65: 772-784.
19. Endicott J, Spitzer RL, Fleiss JL, Cohen J (1976). The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33: 766-771.
20. First MSpitzer RGibbon MWilliams J (eds) (1999). Entrevista Cĺinica Estructurada Para los Trastornos del eje-I del DSM-IV. Masson: Barcelona.
21. Frodl T, Amico F (2013). Is there an association between peripheral immune markers and structural/functional neuro-imaging findings? Prog Neuropsychopharmacol Biol Psychiatry (http://dx.doi.org/10.1016/j.pnpbp.2012.12. 013).
22. Gage SH, Zammit S, Hickman M (2013). Stronger evidence is needed before accepting that cannabis plays an important role in the aetiology of schizophrenia in the population. F1000 Med Rep 5: 2.
23. Garcia-Bueno B, Bioque M, Mac-Dowell KS, Barcones MF, Martinez-Cengotitabengoa M, Pina-Camacho L et al (2013). Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia. Schizophr Bull (e-pub ahead of print 13 March 2013).
24. Garcia-Rizo C, Fernandez-Egea E, Oliveira C, Justicia A, Bernardo M, Kirkpatrick B (2012). Inflammatory markers in antipsycho-tic-naive patients with nonaffective psychosis and deficit vs. nondeficit features. Psychiatry Res 198: 212-215.
25. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ (2010). International consensus study of antipsychotic dosing. Am J Psychiatry 167: 686-693.
26. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J et al (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29: 2108-2114.
27. Giuffrida A, Seillier A (2012). New insights on endocannabinoid transmission in psychomotor disorders. Prog Neuropsychophar-macol Biol Psychiatry 38: 51-58.
28. Henquet C, Murray R, Linszen D, van Os J (2005). The environment and schizophrenia: the role of cannabis use. Schizophr Bull 31: 608-612.
29. Hillard CJ, Weinlander KM, Stuhr KL (2012). Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience 204: 207-229.
30. Ho BC, Wassink TH, Ziebell S, Andreasen NC (2011). Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia. Schizophr Res 128: 66-75.
31. Hollingshead ABRedlich FC (eds) (1958). Social Class and Mental Illness. Wiley: New York.
32. IBM Corp (2011). IBM SPSS Statistics for Windows. IBM Corp.: Armonk, NY.
33. Insel TR (2010). Rethinking schizophrenia. Nature 468: 187-193.
34. Ishiguro H, Horiuchi Y, Ishikawa M, Koga M, Imai K, Suzuki Y et al (2010). Brain cannabinoid CB2 receptor in schizophrenia. Biol Psychiatry 67: 974-982.
35. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP et al (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371: 1085-1097.
36. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
37. Kirkpatrick B (2009). The Concept of Schizophrenia. Rev Psiquiatr Salud Ment 2: 105-107.
38. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L et al (2003). The cannabinoid system and immune modulation. J Leukoc Biol 74: 486-496.
39. Koethe D, Giuffrida A, Schreiber D, Hellmich M, Schultze-Lutter F, Ruhrmann S et al (2009). Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry 194: 371-372.
40. Kokkevi A, Hartgers C (1995). EuropASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur Addict Res 1: 208-210.
41. Koskinen J, Lohonen J, Koponen H, Isohanni M, Miettunen J (2009). Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull 36: 1115-1130.
42. Lazenka MF, Selley DE, Sim-Selley LJ (2012). Brain regional differences in CB1 receptor adaptation and regulation of transcription. Life Sci 92: 446-452.
43. Lazzarin N, Valensise H, Bari M, Ubaldi F, Battista N, Finazzi-Agro A et al (2004). Fluctuations of fatty acid amide hydrolase and anandamide levels during the human ovulatory cycle. Gynecol Endocrinol 18: 212-218.
44. Leweke FM, Giuffrida A, Koethe D, Schreiber D, Nolden BM, Kranaster L et al (2007). Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res 94: 29-36.
45. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (1999). Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10: 1665-1669.
46. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C et al (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2: e94.
47. McGeer PL, Itagaki S, Akiyama H, McGeer EG (1988). Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 24: 574-576.
48. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D (2004). A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2: 13.
49. Meyer U, Schwarz MJ, Muller N (2011). Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther 132: 96-110.
50. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
51. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M et al (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370: 319-328.
52. Nong L, Newton C, Cheng Q, Friedman H, Roth MD, Klein TW (2002). Altered cannabinoid receptor mRNA expression in peripheral blood mononuclear cells from marijuana smokers. J Neuroimmunol 127: 169-176.
53. Ortega-Alvaro A, Aracil-Fernandez A, Garcia-Gutierrez MS, Navarrete F, Manzanares J (2011). Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice. Neuropsychopharmacology 36: 1489-1504.
54. Perry VH, Cunningham C, Holmes C (2007). Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 7: 161-167.
55. Rollins B, Martin MV, Morgan L, Vawter MP (2010). Analysis of whole genome biomarker expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 153B: 919-936.
56. Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM et al (2012). Identification of a biological signature for schizophrenia in serum. Mol Psychiatry 17: 494-502.
57. Seillier A, Advani T, Cassano T, Hensler JG, Giuffrida A (2010). Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. Int J Neuropsychopharmacol 13: 373-386.
58. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H et al (1983). A children's global assessment scale (CGAS). Arch Gen Psychiatry 40: 1228-1231.
59. Sugranyes G, Flamarique I, Parellada E, Baeza I, Goti J, Fernandez-Egea E et al (2009). Cannabis use and age of diagnosis of schizophrenia. Eur Psychiatry 24: 282-286.
60. Torrey EF, Bartko JJ, Yolken RH (2012). Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophr Bull 38: 642-647.
61. Volkow ND (2009). Substance use disorders in schizophrenia-clinical implications of comorbidity. Schizophr Bull 35: 469-472.
62. Wolf SA, Tauber S, Ullrich O (2008). CNS immune surveillance and neuroinflammation: endocannabinoids keep control. Curr Pharm Des 14: 2266-2278.
63. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978). A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133: 429-435.
64. Zamberletti E, Rubino T, Parolaro D (2012). The endocannabinoid system and schizophrenia: integration of evidence. Curr Pharm Des 18: 4980-4990.
65. Zoppi S, Perez Nievas BG, Madrigal JL, Manzanares J, Leza JC, Garcia-Bueno B (2011). Regulatory role of cannabinoid receptor 1 in stress-induced excitotoxicity and neuroinflammation. Neuropsychopharmacology 36: 805-818.